Education 【 display / non-display 】

Education 【 display / non-display 】

• 　

  -

  1987

  University of Tsukuba   医学部  

• 　

  -

  1987

  University of Tsukuba   Faculty of Medicine  

Degree 【 display / non-display 】

Degree 【 display / non-display 】

• 筑波大学   博士(医学)

Professional Memberships 【 display / non-display 】

Professional Memberships 【 display / non-display 】

• 　

  　

  　

  日本癌治療学会

• 　

  　

  　

  日本医療情報学会

• 　

  　

  　

  日本臨床疫学会

• 　

  　

  　

  日本臨床試験学会

• 　

  　

  　

  JAPANESE SOCIETY FOR PHARMACOEPIDEMIOLOGY

display all >>

Research Areas 【 display / non-display 】

Research Areas 【 display / non-display 】

• Life sciences   Urology  

• Life sciences   Pharmacology  

• Life sciences   Hygiene and public health (non-laboratory)  

• Life sciences   Hygiene and public health (laboratory)  

• Life sciences   Healthcare management, medical sociology  

Affiliation 【 display / non-display 】

Affiliation 【 display / non-display 】

• Sapporo Medical University   Biostatistics and Data Management   Professor  

Papers 【 display / non-display 】

Papers 【 display / non-display 】

• Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.

  Kazuyuki Mori, Shingo Hatakeyama, Hideki Enokida, Hideaki Miyake, Eiji Kikuchi, Hiroyuki Nishiyama, Tomohiko Ichikawa, Takao Kamai, Yasushi Kaji, Haruki Kume, Tsunenori Kondo, Hideyasu Matsuyama, Naoya Masumori, Akihiro Kawauchi, Atsushi Takenaka, Hirotsugu Uemura, Masatoshi Eto, Norio Nonomura, Yasuhisa Fujii, Shiro Hinotsu, Chikara Ohyama

  International journal of urology : official journal of the Japanese Urological Association   31 ( 3 ) 194 - 207  2024.03  [International journal]

  　View Summary

  This article is an English translation of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma (2nd edition) published in June 2023. The Japanese Urological Association's (JUA) Guidelines Committee on Upper Tract Urothelial Carcinoma (UTUC) created a 2023 update guideline to support clinicians' current evidence-based management of UTUC and to incorporate its recommendations into clinical practice. The new guideline adhered as closely as possible to the Minds Manual for Guideline Development 2020 ver. 3.0. Findings related to epidemiological, pathological, diagnosis, treatment, and follow-up were reviewed. In addition, seven clinical questions (CQs) were set to determine the grade of recommendation and level of evidence. Preconceptions and biases were removed from the preparation process, the overall evidence was evaluated appropriately, and recommendations were made after fully considering the balance between benefits and harms. Although the evidence is still insufficient to be taken up as a CQ, the latest important information is described in seven columns, and clinical issues that should be resolved in the future related to the CQ are described as recommendations for tomorrow. We hope that these guidelines will help medical professionals, patients, and their families involved in the treatment of UTUC in their decision-making, and hope that a critical review of these guidelines will lead to further refinements in the next edition.

  DOI PubMed

• A feasibility study of provider-level implementation strategies to improve access to colorectal cancer screening for patients with schizophrenia: ACCESS2 (N-EQUITY 2104) trial.

  Masaki Fujiwara, Yuto Yamada, Tsuyoshi Etoh, Taichi Shimazu, Masafumi Kodama, Norihito Yamada, Takahiro Asada, Shigeo Horii, Takafumi Kobayashi, Teruo Hayashi, Yoshitaka Ehara, Kenji Fukuda, Keita Harada, Maiko Fujimori, Miyuki Odawara, Hirokazu Takahashi, Shiro Hinotsu, Naoki Nakaya, Yosuke Uchitomi, Masatoshi Inagaki

  Implementation science communications   5 ( 1 ) 2 - 2  2024.01  [Refereed]  [International journal]

  　View Summary

  BACKGROUND: People with schizophrenia have a lower colorectal screening rate than the general population. A previous study reported an intervention using case management to encourage colorectal cancer screening for patients with schizophrenia in psychiatric outpatient settings. In this feasibility study, we developed provider-level implementation strategies and evaluated the feasibility of conducting a definitive trial in terms of the penetration of the intervention assessed at the patient level. Additionally, we examined the fidelity of strategies to implement the intervention at the provider level in a routine clinical psychiatric setting. METHODS: This was a multicenter, single-arm feasibility study with medical staff at psychiatric hospitals in Japan. The provider-level implementation strategies developed in this study included three key elements (organizing an implementation team appointed by the facility director, interactive assistance using a clear guide that outlines who in the hospital should do what, and developing accessible educational materials) to overcome major barriers to implementation of the intervention and four additional elements (progress monitoring, joint meetings and information sharing among participating sites, adaptation of encouragement methods to specific contexts, and education of on-site staff), with reference to the elements identified in the Expert Recommendations for Implementing Change (ERIC). The feasibility of the strategies was evaluated by the proportion of patients who were eligible for encouragement (patients with schizophrenia aged 40, 50, or 60) who received encouragement. We set the goal of providing encouragement to at least 40% of eligible patients at each site. RESULTS: Two public and four private psychiatric hospitals in Okayama and Shimane prefectures participated in this study. Regarding fidelity, all elements of the strategies were conducted as planned. Following the procedures in the guide, each team prepared and provided encouragement according to their own facility and region. Penetration, defined as the proportion of eligible patients who received encouragement, ranged from 33.3 to 100%; five of the six facilities achieved the target proportion. CONCLUSIONS: The provider-level implementation strategies to implement encouragement were feasible in terms of penetration of the intervention assessed at the patient level. The results support the feasibility of proceeding with a future definitive trial of these strategies. TRIAL REGISTRATION: jRCT, jRCT1060220026 . Registered on 06/04/2022.

  DOI PubMed

• Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational Analysis.

  Tsukasa Higashionna, Keisaku Harada, Akinari Maruo, Takahiro Niimura, Elizabeth Tan, Quynh Thi Vu, Takayoshi Kawabata, Soichiro Ushio, Hirofumi Hamano, Makoto Kajizono, Yoshito Zamami, Keisuke Ishizawa, Ko Harada, Shiro Hinotsu, Mitsunobu R Kano, Hideharu Hagiya, Toshihiro Koyama

  Cancers   15 ( 15 )  2023.07  [International journal]

  　View Summary

  Globally, the numbers of head and neck cancer (HNC) cases and related deaths have recently increased. In Japan, few studies have examined crude or age-adjusted HNC mortality rates. Therefore, this study aimed to determine the trends in crude and age-adjusted mortality rates for HNC per million individuals in Japan from 1999 to 2019. Data on HNC-associated deaths were extracted from the national death certificate database using the International Classification of Diseases, Tenth Revision (n = 156,742). HNC mortality trends were analysed using joinpoint regression models to estimate annual percentage change (APC) and average APC (AAPC). Among men, no significant change was observed in the age-adjusted death rate trend from 1999 to 2014; however, a marked decrease was observed from 2014 to 2019. No changing point was observed in women. Age-adjusted mortality rates continuously decreased over the 21-year period, with an AAPC of -0.7% in men and -0.6% in women. In conclusion, the overall trend in age-adjusted rates of HNC-associated deaths decreased, particularly among men, in the past 5 years. These results will contribute to the formulation of medical policies to develop targeted screening and prevention programmes for HNC in Japan and determine the direction of treatment strategies.

  DOI PubMed

• Increasing disparities in cancer screening among people with severe mental illness during the COVID-19 pandemic.

  Masaki Fujiwara, Yuto Yamada, Taichi Shimazu, Naoki Nakaya, Shiro Hinotsu, Maiko Fujimori, Yosuke Uchitomi, Masatoshi Inagaki

  Schizophrenia research   258   18 - 20  2023.07  [International journal]

  DOI PubMed

• A multicenter, retrospective observational study investigating baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer treated with primary androgen deprivation therapy.

  Satoru Taguchi, Mizuki Onozawa, Shiro Hinotsu, Taketo Kawai, Takeshi Mitomi, Satoshi Uno, Haruki Kume

  Japanese journal of clinical oncology   53 ( 10 ) 957 - 965  2023.07  [International journal]

  　View Summary

  OBJECTIVE: This multicenter, retrospective, observational study investigated baseline characteristics and clinical outcomes in patients with hormone-sensitive prostate cancer who received primary androgen deprivation therapy, using Japan Study Group of Prostate Cancer registry data. METHODS: Among patients in the Japan Study Group of Prostate Cancer registry, those who initiated primary androgen deprivation therapy and were aged 20 years or older were enrolled in this study. The primary endpoint was time to disease progression, defined as time from primary androgen deprivation therapy initiation to either prostate-specific antigen or clinical progression. Secondary endpoints included prostate-specific antigen progression-free survival, prostate-specific antigen response (90% or greater reduction from baseline) and distribution of second-line treatment. RESULTS: Of the 2494 patients (goserelin, n = 564; leuprorelin, n = 1148; surgical castration, n = 161; degarelix, n = 621), those who received degarelix had higher prostate-specific antigen levels and Gleason scores and were at a more advanced clinical stage than those receiving goserelin or leuprorelin. The median time to disease progression (identical to the prostate-specific antigen progression-free survival result) was not reached for goserelin and leuprorelin, 52.7 months for surgical castration and 54.0 months for degarelix. Although baseline prostate-specific antigen values in the degarelix cohort were higher than those of the leuprorelin or goserelin cohorts, prostate-specific antigen responses were not different among the three cohorts. Regarding second-line treatment, the largest patient group received degarelix followed by leuprorelin (n = 195). CONCLUSIONS: This study clarified patient characteristics and long-term effectiveness of primary androgen deprivation therapy in real-world clinical practice. Japanese urologists appear to select appropriate primary androgen deprivation therapy based on patient background and tumour characteristics, with degarelix largely reserved for higher risk patients.

  DOI PubMed

display all >>

Misc 【 display / non-display 】

Misc 【 display / non-display 】

• Late recurrence in patients with non-muscle-invasive bladder cancer after 5-year cancer-free periods.

  Yurie Hirata, Madoka Higuchi, Takahiro Osawa, Shiro Hinotsu, Toru Harabayashi, Tango Mochizuki, Nobuyasu Enami, Osamu Nounaka, Yuichiro Shinno, Hiroshi Kikuchi, Ryuji Matsumoto, Takashige Abe, Sachiyo Murai, Nobuo Shinohara

  International journal of urology : official journal of the Japanese Urological Association ( LIPPINCOTT WILLIAMS & WILKINS )  203 ( 10 ) E1079 - E1080  2022.05  [International journal]

  　View Summary

  OBJECTIVES: There is no consensus about the follow-up schedule after 5-year cancer-free periods. In this study, we aimed to elucidate the risk factors for the recurrence in patients with non-muscle-invasive bladder cancer who remained cancer free for more than 5 years. METHODS: Data from six Japanese institutions were retrospectively reviewed. Among the patients with non-muscle-invasive bladder cancer who were treated with transurethral resection of bladder tumor between 1990 and 2013, those who had no recurrence for more than 5 years were included in this study. The Kaplan-Meier method and Cox hazards model were used to estimate recurrence-free survival and to determine the pathologic and clinical factors affecting late recurrence. RESULTS: In total, 434 patients were enrolled in this study. Of these patients, 55 patients (12.7%) experienced late recurrence. The median follow-up time was 8.9 years (interquartile range 6.9-11.3 years). Prior history of bladder cancer before the most recent transurethral resection was a significant predictor for late recurrence (hazard ratio 1.99 [95% confidence interval 1.13-3.47], P = 0.019), although other clinical factors including tumor grade, pathologic stage, tumor multiplicity, and current risk classification systems were not associated with late recurrence. CONCLUSIONS: Late recurrence after a long tumor-free period is not rare and it was not predicted by current risk classification systems. Only prior history of bladder cancer was a significant predictor for late recurrence in this study.

  DOI PubMed

• Update of treatment strategy with new androgen receptor inhibitors for nonmetastatic castration-resistant prostate cancer (M0CRPC): On the basis of the final overall survival results from the phase III clinical trials including ARAMIS study

  鈴木和浩, 上村博司, 鈴木啓悦, 樋之津史郎, 大家基嗣

  泌尿器外科   33 ( 11 )  2020

  J-GLOBAL

• Personalized peptide vaccination for castration resistant prostate cancer progressing after docetaxel chemotherapy: A randomized, double-blind, placebo controlled, phase III trial.

  Masanori Noguchi, Kiyohide Fujimoto, Gaku Arai, Hiroji Uemura, Katsuyoshi Hashine, Hiroaki Matsumoto, Satoshi Fukasawa, Hideomi Nakatsu, Atsushi Takenaka, Masato Fujisawa, Hirotsugu Uemura, Seiji Naito, Shin Egawa, Hiroyuki Fujimoto, Shiro Hinotsu, Kyogo Itoh, Yasuo Kohjimoto

  JOURNAL OF CLINICAL ONCOLOGY ( AMER SOC CLINICAL ONCOLOGY )  37 ( 15 )  2019.05

  Research paper, summary (international conference)  

  DOI

• ガイドライン・取り扱い規約作成にあたっての連携

  大家 基嗣, 鈴木 和浩, 篠原 信雄, 石塚 修, 樋之津 史郎, 関根 芳岳

  日本泌尿器科学会雑誌 ( (一社)日本泌尿器科学会 )  109 ( Suppl. ) S58 - S59  2018.11

• 非弁膜症性心房細動患者における医療費に関する研究

  大島 礼子, 野村 和喜, 小山 敏弘, 座間味 義人, 樋之津 史郎, 狩野 光伸

  日本薬学会年会要旨集 ( (公社)日本薬学会 )  138年会 ( 4 ) 185 - 185  2018.03

display all >>

Research Projects 【 display / non-display 】

Research Projects 【 display / non-display 】

• 医療データサイエンスによる高齢者医療の疾病構造に関する臨床疫学研究

  基盤研究(C)

  Project Year :

  2022.04

  -

  2025.03

   

  小山 敏広, 萩谷 英大, 座間味 義人, 樋之津 史郎

• Clinical epidemiological study on disease structure and quality assessment of healthcare for the older population by utilizing healthcare big data

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2019.04

  -

  2022.03

   

  Koyama Toshihiro

  　View Summary

  The purpose of this study was to analyze the actual situation of medical care for the elderly from a long-term perspective by utilizing medical big data covering the entire population and integrating clinical epidemiological methods. As studies utilizing medical big data of the entire population targeting the elderly, we have clarified diseases that could be targeted, and published clinical epidemiological studies on influenza, heptitis C, adverse reaction-related deaths, amyloidosis, and sarcoidosis in international journals, respectively.

• Construction of Academic Foundations and Development of a Curriculum for the Creation of Medical Ethics of Hansen's disease

  Grant-in-Aid for Scientific Research (B)

  Project Year :

  2018.04

  -

  2021.03

   

  KONDO Makiko

  　View Summary

  In Japan, patients with Hansen‘s disease were forcibly detained, followed by lifetime isolation. To prevent the same mistakes, it is necessary to establish medical ethics for Hansen‘s disease. This project primarily constructed a curriculum on "Hansen‘s disease and Medical Ethics" (for medical students), and on “Hansen‘s disease and Human Dignity” (for elementary to university students), which initiated a series of on-site lectures. Subsequent qualitative analysis of survival narratives elucidated the ethical issues of lost sight due to clinical trials, the structure of spiritual pain from lifelong isolation, perceptual disorders, and their perception of the COVID-19 pandemic. Our published book, "The Beauty of Nature and Prayer in Sanatoriums," and the digital teaching materials, convey the wisdom gained through a life of hardship. Finally, the Society for the Ethics of Hansen‘s disease was established, and the journal “Hansen‘s disease and Human Dignity” was published.

• Development of a method for validating epidemiological research results using a large-scale claim database.

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2016.04

  -

  2020.03

   

  Hinotsu Shiro

  　View Summary

  The claim database was obtained from JMDC. Between January 2005 and July 2017, there were 5,767 patients diagnosed prostate cancer. The total number of hospitals was 17,001, of which 14,487 (85.2%) were clinics with 0-19 beds. The total number of medical prescriptions was 1,426,115. Among them, the drugs used for the treatment of prostate cancer, 4,288 cases of Leuplin, 4,220 cases of Casodex tablets (6,680 generic products), 3,155 cases of Zoradex, and 1,028 cases of Odyne tablets (424 generic products). The total number of laboratory tests was 5,225,046, with Creatinine 91,672, AST 85,736, ALT 85,523, and PSA 7,877. It was considered that this large-data could be used to estimate the risk of adverse events occurring in renal and liver functions.

• Development of risk table of recurrence after TURBT for non-muscle bladder cancer in Japan using the method of meta-analysis

  Grant-in-Aid for Scientific Research (C)

  Project Year :

  2012.04

  -

  2015.03

   

  HINOTSU Shiro, AKAZA Hideyuki

  　View Summary

  I developed the system for searching the literature on recurrence of the non-muscle invasive bladder cancer performed in Japan. The database used MEDLINE (PubMed) and a Igaku Chuo Zasshi (Ichushi Web). I developed the software which saves the dounloaded file of PubMed and Ichusi Web with a standardized format. I downloaded the paper which contains "Superficial" in a paper title, and the paper containing "Non-muscle invasive" using this software. And I verified that this software operated normally. Moreover, I prepared the Cloud server for saving these files, and saved data. From now on, I release this technique and will enable use of the developed software.

display all >>